The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy.

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 25 Sep 2017

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Ezetimibe/simvastatin (Primary) ; Simvastatin
Indications Dyslipidaemias; Hypercholesterolaemia; Lipid metabolism disorders
Focus Therapeutic Use
Acronyms VICTORY

01 Sep 2017 Results published in the Nutrition, Metabolism and Cardiovascular Diseases
29 Apr 2009 Actual initiation date changed from Jan 2009 to Nov 2008 as reported by ClinicalTrials.gov.
29 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com